Review Article
Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies
Table 3
Clinical data from studies with the main multi-target agents in clinical development for the treatment of medullary thyroid cancer.
| Author (ref) | Pharmaceutical compound | | Response rate (%) | Stabilizations (%) | Progression-free survival (months) |
|
Wells Jr. et al. [28] | Vandetanib | 231 | 45 | — | Not achieved at 24 months. HR versus placebo = 0.46 |
Kurzrock et al. [29] | Cabozantinib | 37 | 49 | 41 | Not reported |
Lam et al. [30] | Sorafenib | 16 | 6 | 62 | 17.9 |
Capdevila et al. [20] | Sorafenib | 34 (15 MTC) | 47 | 40 | 10.5 |
Schlumberger et al. [31] | Motesanib | 91 | 2 | 48 | 11.2 |
Carr et al. [23] | Sunitinib | 7 | 37.5 | — | Not reported |
De Souza et al. [32] | Sunitinib | 25 | 35 | 57 | Not reported |
|
|